Advice

following an abbreviated submission:

daratumumab subcutaneous injection (Darzalex®) is accepted for use within NHSScotland.

Indication under review: in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Following a submission under the orphan medicine process, SMC has previously accepted daratumumab concentrate for solution for infusion in combination with bortezomib, thalidomide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (SMC2302).

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

 

Download detailed advice728KB (PDF)

Download

Medicine details

Medicine name:
daratumumab (Darzalex)
SMC ID:
SMC2326
Indication:

In combination with bortezomib, thalidomide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Status
Accepted
Date advice published
18 January 2021